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Abstract 
 
Background: 
Shared medical appointments are a series of one-to-one doctor-patient contacts, in 
presence of a group of 6-10 fellow patients. This group visits substitute the annual 
control visits of patients with the neurologist. The same items attended to in a one-to- 
one appointment are addressed. The possible advantages of a shared medical 
appointment could be an added value to the present management of neuromuscular 
patients. The currently problem-focused one-to-one out-patient visits often leave little 
time for the patient’s psychosocial needs, patient education, and patient 
empowerment.  
Methods/ design: 
A randomized, prospective controlled study (RCT) with a follow up of 6 months will 
be conducted to evaluate the clinical and cost-effectiveness of shared medical 
appointments compared to usual care for 300 neuromuscular patients and their 
partners at the Radboud University Nijmegen Medical Center. Every included patient 
will be randomly allocated to one of the two study arms. This study has been 
reviewed and approved by the medical ethics committee of the region Arnhem-
Nijmegen, the Netherlands.  The primary outcome measure is quality of life as 
measured by the EQ-5D, SF-36 and the Individualized neuromuscular Quality of Life 
Questionnaire. The primary analysis will be an intention-to-treat analysis on the area 
under the curve of the quality of life scores. A linear mixed model will be used with 
random factor group and fixed factors treatment, baseline score and type of 
neuromuscular disease. For the economic evaluation an incremental cost-effectiveness 
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analysis will be conducted from a societal perspective, relating differences in costs to 
difference in health outcome. Results are expected in 2012. 
Discussion: 
This study will be the first randomized controlled trial which evaluates the effect of 
shared medical appointments versus usual care for neuromuscular patients.  This will 
enable to determine if there is additional value of shared medical appointments to the 
current therapeutical spectrum. When this study shows that group visits produce the 
alleged benefits, this may help to increase the acceptance of this innovative and 
creative way of using one of the most precious resources in health care more 
efficiently: time.  
Trial registration:  DutchTrial Register www.trialregister.nl NTR1412 
 Background  
Introduction 
As of January 2006, the department of neurology at the RUNMC has started offering 
shared medical appointments or group visits to patients with a neuromuscular disease. 
This novel approach of delivering outpatient care is now being compared with usual 
care during a randomized controlled trial with 300 patients and their partners. The 
focus in this trial is on health outcomes and costs. 
 
Motive 
Most neuromuscular diseases are chronic progressive diseases necessitating periodic 
specialized care. Because of the progressive nature of the disease, existing symptoms 
aggravate over time and new symptoms may develop over time, requiring adjustment 
of management, and giving rise to new questions on the part of the patient and his or 
her partner. In the absence of definitive cures for chronic neuromuscular diseases, the 
improvement of quality of life, patient- and partner satisfaction with care, self 
management and functional capacity become key objectives of care. Currently, these 
patients attend the out-patient clinic at regular intervals (usually annually), where they 
are seen in one-to-one patient- physician encounters. It is difficult, however, to fulfill 
the complex needs of neuromuscular patients in these brief, problem-focused out-
patient visits which leave little time for the patient's psychosocial needs, patient 
education, and patient empowerment. The possible advantages of a shared medical 
appointment could be an answer to these questions.  Our hypotheses are that shared 
medical appointments show 1) the same effect on the development of the disease as 
individual appointments 2) an improvement of self-efficacy as opposed to individual 
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appointments, therefore resulting in an improved quality of life 3) better use of 
resource utilization and 4) a positive effect on self efficacy and quality of life of the 
partner as well as on the relationship.[1-6] 
 
What is a shared medical appointment? 
During a shared medical appointment or group visit, 6-10 patients and their partners 
are seen simultaneously by a physician who is supported by a group mentor. Shared 
medical appointments are a series of one on one doctor-patient contacts, in presence 
of a group fellow patients. A group visit takes  1,5 – 2 hours and substitutes the 
annual control visit of the patients. The same items the neurologist attends to in a one 
to one appointment are addressed. The physician has more time to give information 
and patients and partners can ask questions to- and learn from their fellow patients. 
The group mentor facilitates the group process, fosters interaction between patients 
and manages time. Shared medical appointments should not be confused with group 
education or peer support groups. As opposed to a group visit, these meetings do not 
substitute for the periodic consultation with the clinician. [7-8] 
Experience with shared medical appointments in patients with diabetes, heart failure, 
bone marrow transplantation and chronically ill older patients have been reported [9-
14]. Evidence of group visits for neurological patients is at this moment at  the level 
of a feasibility trial for patients with Parkinson disease[15]. 
Methods/design 
A randomized, prospective controlled study (RCT) with a follow up of 6 months will 
be conducted to evaluate the clinical and cost-effectiveness of shared medical 
appointments compared to usual care for neuromuscular patients. The trial flow of the 
proposed subject enrolment and randomization procedures are shown in Figure 1.  
Study population 
The aim is to include 270 evaluable patients with one of the following chronic 
neuromuscular diseases:  
- Myotonic Dystrophy type 1 genetically determined (classic and  juvenile type) 
[16]; 
- McArdles disease, Glycogen Storage Disease Type V. Biochemically and 
genetically determined; 
- Facioscapulohumeral Muscular Dystrophy (FSHD), genetically determined; 
- Chronic  progressive external ophthalmoplegia (CPEO) as defined by Emery [17]; 
- Oculopharyngeal Muscular Dystrophy (OPMD), genetically determined; 
- Inclusion body myositis (IBM) as defined by Badrising and Verschuuren [18-19] 
- Non-dystrophic myotonias. These skeletal muscle channelopathies include two 
main groups:  the chloride and sodium channelopathies [20]; 
- Myositis: Dermatomyositis and Polymyositis [21] 
- Polyneuropathy: CMT1 and HNPP [22] 
 
The partners of these patients will also be included. All patients will be identified by 
CRAMP, a neuromuscular database containing data from over 4500 patients with 
neuromuscular disease attending the outpatient clinic of the Radboud University 
Nijmegen Medical Center[23]. From this database, patients who meet the inclusion 
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criteria (table 1) will be contacted by telephone by the primary investigator (FS) to 
inform them about the study and ask permission to send information and informed 
consent forms. If the patient decides not to participate in the study, the reason will be 
asked and documented. If written consent forms are not returned within 3 weeks, 
patients will receive a reminder phone call.  After written informed consent is 
obtained, patients and their partners are randomized to one of the two study arms. 
Reasons for drop-out will be asked and documented. 
 
Ethical approval and registration 
This study has been reviewed and approved by the medical ethics committee of the 
region Arnhem-Nijmegen, the Netherlands. (reference CMO nr. 2008/224) and has 
been registered in the NTR (Dutch Trial Registration nr NTR1412) Patients and their 
partners receive verbal and written information about the study and written informed 
consent will be obtained before randomization. 
 
Randomization and blinding 
Concealed randomization will be performed through computer-generated 
randomization software. Every included patient will be randomly allocated to one of 
the two study arms by the computer. The method of simple randomization is applied. 
In view of the nature of the interventions, blinding of the participants, participating 
neurologists and primary researcher is not possible. The statistician who conducts the 
analysis of the data will, however, be blinded for the patients’ groups.  
 
Interventions 
Care as usual: individual outpatient appointment. 
Patients and partners who are randomized to the control group will have their regular 
control visit with one of the participating neuromuscular neurologists at the outpatient 
neurology department of the RUNMC. This one on one control visit substitutes the 
regular annual control visit the patients pay to the neurology department. The same 
items that are normally attended to during the control visit, are attended to by the 
neurologist. All physical examinations, prescriptions and referrals are conducted as 
deemed appropriate, and documented in the patient record. The regular one on one 
control visit takes 30 minutes.  
 
Intervention: shared medical appointment 
Patients and partners who are randomized to the intervention arm of the study will be 
invited to a shared medical appointment of 1,5 - 2 hours with one of the participating 
neuromuscular neurologists and a group mentor at the outpatient neurology 
department of the RUNMC. The same neurologists execute the individual 
appointments and the shared medical appointments.  As well as for the individual 
appointments, the shared medical appointments substitute for the annual control visit 
of the patients. The same items the neurologist attends to in a one on one control visit 
are attended to during the shared medical appointment. The neurologist is supported 
by a group mentor, who facilitates the group process, fosters interaction between 
patients and manages time.  
The group mentor starts with a short introduction in which the process of the shared 
medical appointment is explained and confidentiality is emphasized. Patients and their 
partners are asked to fill out a privacy form, which is kept in the patient’s records, in 
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order to emphasize the confidentiality of the group visit. If physical examinations are 
deemed necessary, they are conducted in a private examination room close to the 
group visit room directly after the shared medical appointment. Necessary 
prescriptions, referrals, and chart notes are being taken care of during or directly after 
the shared medical appointment. The neurologists have received training in 
conducting shared medical appointments prior to the study. The process of the shared 
medical appointments is described in appendix 1. 
 
Compliance and attrition 
When participants indicate that they wish to discontinue their participation in the 
study, reasons will be documented. 
 
Outcomes 
Outcome measures for patients are listed in table 2. The primary outcome measure is 
quality of life ( daily activity limitations, pain, mood, fatigue, social activities) as 
measured by the EQ-5D, SF-36 and the Individualized neuromuscular Quality of Life 
Questionnaire (INQoL). For the SF-36 and EQ 5 D,  normative scores are available 
based on the Dutch population. For the INQoL, no Dutch version was available. With 
granted authorization from the authors, a translation into the Dutch language was 
made [24-27].  Secondary outcome measures are (1) Use of health care resources (use 
of health care services, medication, compliance with medication, use of assistance 
with daily activities) Questions from the Client Service Receipt Inventory (CSRI) are 
used to record service utilization [28]. (2) Self efficacy (how much confidence one 
has in being able to execute specific behaviour), as measured by the Self Efficacy 
questionnaire from Schwarzer [29]. This is a 10-item psychometric scale that is 
designed to assess self-beliefs to cope with a variety of difficult demands in life. Also, 
a questionnaire to measure self efficacy of patients with neuromuscular disease was 
developed by the research group. (3) The need for social support was assessed by 
using the subscale emotional support of the Dutch questionnaire SSLD (Sociale Steun 
Lijst-Discrepanties) from Sanderman and van Sonderen [30]. (4) Satisfaction with 
relationship was measured by asking the participants to rate their relationship on a 1/ 
10 scale and to rate their relationship on a VAS scale, ranging from the worst possible 
relationship to the best possible relationship[31] (5) Satisfaction with and aspects of 
the visit, as measured by The QUality Of care Through the patient’s Eyes (QUOTE) 
questionnaire [32]. The severity of the disease as measured through the Rankin-scale 
is assessed during the shared medical appointments and through reviewing the chart 
notes for individual appointments by the participating neurologists or primary 
researcher[33-34].  
 
Outcome measures for partners are listed in table 3. Among partners of patients, 
quality of life (EQ-5D) [24-27], self efficacy (SE questionnaire by Schwarzer, [29]), 
the need for social support (subscale emotional support of the Dutch questionnaire 
SSLD [30], satisfaction with the relationship (VAS scale and 1-10 reporting)[31] , 
objective burden of care and  satisfaction with and aspects of the visit (QUOTE 
questionnaire, [32])will be measured. Ojective burden of care is measured by asking 
after the amount of time a partner spends on caring for the partner and on doing 
household tasks in order to be able to relieve or support their partner with the chronic 
disease; time spent on delivering care for the chronically ill partner is the main 
predictor for the impact of the disease on the life of the partner[35].   
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Economic evaluation 
 
Cost effectiveness will be assessed from a societal perspective. Direct neuromuscular 
disease-related costs health care costs, including costs of outpatient care, physical-, 
speech- and occupational therapy, additional visits to other health care providers 
(GPs, specialist care, etc.), district nursing, receipt of aids and adaptations, 
prescription medication, professional home care and hospitalization will be included, 
as well as non-health care costs such as costs for paid and unpaid help. For unit cost 
prices, standard rates will be adopted from the national guideline  [36]or real cost 
prices (e.g., for medication) will be obtained through the website of the Dutch Health 
Care Insurance Board (CVZ, www.medicijnkosten.nl). For shared medical 
appointments, a cost price will be calculated on the basis of available standard rates 
and real expenditures. The price year will be 2009, the currency Euros, and in view of 
the timescale of the study, costs and health benefits will not be discounted. Utilization 
of itemized resources over the trial period will be self-recorded by patients with a 
modified version of the Client Service Receipt Inventory (CSRI)[28]. Costs per 
patient will be calculated by multiplying resource volumes by unit costs. 
 
Outcome measures will be obtained through standardized questionnaires, who patients 
and partners fill out at home at the start of the study period (T0), 1 week (T1), 3 
months (T2) and 6 months after the intervention (T3). See figure 1 and table 2 and 3. 
At the first measurements (T0) demographic data will be obtained.  
 
Statistical analysis 
Sample size 
On the basis of the literature [37-38] group visits may be expected to lead to a 
clinically relevant improvement in quality of life of 5 points on the total SF-36 score. 
Assuming a standard deviation of 12 [39], 92 patients need to be enrolled in both 
groups to achieve a statistical power of 80% (alpha = 0.05, two-sided). Taking into 
account non-evaluable patients, to adjust for imbalances and to be able to do subgroup 
analysis on age, sex, gender and severity, 135 patients will be enrolled in both groups. 
In order to be able to evaluate 270 patients, the aim is to include 300 patients. 
 
Analysis of outcome measures 
 
300 neuromuscular patients and if applicable their partners will be included in the 
study. The primary analysis will be an intention-to-treat analysis on the area under the 
curve of the quality of life scores (average response during 6 months). A linear mixed 
model will be used with random factor group and fixed factors treatment, baseline 
score and type of neuromuscular disease. Other outcome parameters will be evaluated 
in a similar way and additional per protocol analyses will be carried out. 
For the analyses SPSS version 17 statistical software will be used. A p-value of 0.05 
will be considered statistically significant. Missing data will be imputed using 
multiple imputation techniques.  
 
Economic evaluation  
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An incremental cost-effectiveness analysis will be conducted from a societal 
perspective, relating differences in costs to difference in health outcome as measured 
by the Euroqol-5D, an instrument to evaluate different health states. Bootstrapping 
will be used for pair-wise comparisons in direct health care costs, direct non-health 
care costs, total direct costs, total indirect costs, and total costs between the two 
groups. Confidence intervals will be obtained by conventional re-sampling methods 
(bootstrapping). The cost effectiveness analysis will provide information on the 
marginal costs and effects of shared medical appointments relative to conventional 
one-to-one outpatient visits through the calculation of an incremental cost 
effectiveness ratio. Ratios will include the primary outcome of the trial, i.e., quality of 
life and two secondary outcome parameters; functional activities, and self-efficacy. 
Cost acceptability curves will be calculated showing the probability that the shared 
medical appointment is cost effective at specified ceiling ratios. In situations where 
there is no significant difference in effects, the use of cost-minimization analysis will 
be used for the reporting of cost differences only. Sensitivity analyses will be 
conducted, exploring the sensitivity of the conclusions to various sources of 
uncertainty, including sampling variation (e.g., differences in self-efficacy and 
functional abilities in both groups) and point-estimates (e.g., unit cost prices of major 
cost drivers). 
 
Discussion 
 
To the best of our knowledge, this study will be the first randomized controlled trial 
which evaluates the effect of shared medical appointments versus usual care for 
neuromuscular patients.  Evidence shows that shared medical appointments can have 
substantial added value, deriving not only from sharing a health care professional’s 
time, but also from sharing mutual experiences, particularly for patients with a 
chronic disease [2-3, 40]. In the literature, group visits have been shown to result in 
fewer hospitalizations and emergency visits, increased patient satisfaction and 
increased self-efficacy as compared to usual one-to-one outpatient visits in elderly, 
chronically ill patients (Scott et al. 2004). In patients with diabetes, a randomized 
controlled trial demonstrated an increased frequency of preventive procedures among 
patients attending group visits, resulting in a better general health status as measured 
by the SF-36 [3]. Sadur et al (1999) demonstrated greater satisfaction with diabetes 
care, greater self-efficacy, better glycemic control, and lower service utilization 
among patients with diabetes who were randomly allocated to group visits as 
compared to counterparts who were allocated to usual care. 
 
This study has several strengths. Firstly, shared medical appointments will be 
compared with usual care in a randomized design. This will enable to determine if 
there is additional value of shared medical appointments to the current management 
spectrum. Secondly, this study involves measuring effect of a treatment on partners of 
patients with a neuromuscular disease. Studies from Baanders et al (2007) and 
Timman (2010) show that living with a chronically ill person, specifically with a 
neuromuscular disorder,  has an impact on the partner’s life that goes beyond the 
consequences of care giving, for example consequences on personal life strain, social 
relations, financial burden, and intrinsic rewards[35]. And that marital satisfaction is a 
strong predictor of better wellbeing, both for patients and, even more so, for 
partners[31]. Thirdly, this study aims to determine the cost effectiveness of shared 
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medical appointments as compared to care as usual. In current healthcare time is a 
scarce good. Efficiency goals are on top of every healthcare managers’ list. When 
introducing a new way of delivering care, such as shared medical appointments, this 
preferably is just as or even more efficient than care as usual. Therefore it is important 
to take cost effectiveness of the intervention into account in this study. A limitation of 
this study can be the fact that it is a single center study. This may influence the 
transferability of the research results to other hospitals.  Due to pragmatic and 
financial reasons the follow up time is limited to 6 months. For patients with 
neuromuscular disorders annual control visits are offered, this limits the number of 
shared medical appointments a patient receives during the study to one. Possibly the 
effect of group visits increase when attended several times. With this study design it is 
not possible to show this effect. A reflection of practice in this study, that could be a 
possible limitation, is inclusion of different patient groups. Although patients all have 
a chronic neuromuscular disease, possible differences in effects between patient 
groups could be difficult to show with this study design.  
In conclusion, this study will provide greater insight in the (cost) effectiveness of 
shared medical appointments for neuromuscular patients. The concept of group visits 
or shared medical appointments is a typical example of organizing the delivery of 
health care in a different way, in an attempt to improve patient outcome within the 
limits of available resources. Many attempts at increasing efficiency of health care 
consist of reducing the amount of time health care professionals spend on specific 
activities. Such attempts risk, however, to jeopardize the quality of care[41]. When 
our study shows that group visits produce the alleged benefits, this may help to 
increase the acceptance of this innovative and creative way of using one of the most 
precious resources in health care more efficiently: time.  
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Appendix 1: 
Process of a shared medical appointment: 
 
- Patient registers at the outpatient clinic an led to the group visit room by the group 
mentor 
- Patients are being asked to fill out a privacy form 
- Group mentor starts with a brief introduction, in which the process of an SMA and 
privacy aspects are explained 
- Neurologist starts with consulting the first patient 
- Individual medical needs and questions of the patient are being discussed with the 
neurologist 
- The neurologist gives information to the patient and his/her partner 
- If applicable, the group mentor asks if fellow patients have experiences on this 
subject they want to share or questions they want to ask to fellow patients or the 
neurologist 
- Neurologist finishes consultation with the first patient and writes notes in the 
patient record 
- The neurologist lifts the second patient record and starts with consulting the 
second patient, and so on till all patients have had their consultation 
- The group mentor asks if all questions are answered and if so closes the group 
visit 
- If applicable, physical examination of a patient is being executed by the 
neurologist in a separate room, any necessary receipts or blood samples are being 
taken care of as well 
- Group mentor and neurologist leave the group visit room and fill out patient 
records and patient letters 
Figures 
Figure 1  - flowchart of trial design  
CRAMP database: Computer Registry of All Myopathies and Polyneuropathies 
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INQOL: Individualized Neuromuscular Quality of Life  
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Tables 
Table 1  -  inclusion and exclusion criteria  
Inclusion criteria  
1.  Registered in CRAMP database with one of the following neuromuscular 
diseases  
 Myotonic Dystrophy type 1. genetically proven ( classic and  juvenile type) 
  McArdles disease, Glycogen Storage Disease Type V. Biochemically and 
genetically proven 
  Facioscapulohumeral Muscular Dystrophy (FSHD). genetically determined 
  Chronic  progressive external ophthalmoplegia (CPEO) as defined by Emery  
  Oculopharyngeal Muscular Dystrophy (OPMD) . genetically determined 
  Inclusion body myositis (IBM)as defined by Badrising and Verschuuren. 
  Non-dystrophic myotonias. These skeletal muscle channelopathies include two 
main groups:  the chloride and sodium channelopathies. 
  Myositis: Dermatomyositis and Polymyositis 
  Polyneuropathy: CMT1 & HNPP 
2. Age > 18 years 
3.   Patients and their partners are control patients in care at the department of 
neurology RUNMC 
Exclusion criteria 
1.  Patients or partners with severe hearing problems 
2.  Patients or partners who cannot speak, read or understand the Dutch language 
well 
3.  Patients  and their partner who have had a control visit with a neurologist at the 
neurology department of the RUNMC less than 6 months ago 
 
Table 2  - Outcome measures and instrumentation patients 
  Instruments T0 T1 T2 T3 
Primary outcome measures       
Quality of life EQ5D, SF36, INQOL √ √ √ √ 
Secondary outcome 
measures 
     
Demographic statistics  √    
Severity of the disease Rankin Scale √    
Use of care resources and 
medicine 
Client Service Receipt Inventory (CSRI) √  √ √ 
Self efficacy SE questionnaire from Schwarzer, SE NMD √ √ √ √ 
Social support SSLD (Sociale Steun Lijst-Discrepanties)  √ √ √ √ 
Satisfaction with relationship  √ √ √ √ 
Satisfaction with the 
appointment 
QUality Of care Through the patient’s Eyes 
(QUOTE) 
 √ √ √ 
Table 3  -  Outcome measures and instrumentation partners  
 Instruments T0 T1 T2 T3 
Primary outcome measures       
Quality of life EQ5D √ √ √ √ 
Secondary outcome 
measures 
     
Demographic statistics  √    
Self efficacy SE questionnaire from Schwarzer √ √ √ √ 
Social support SSLD (Sociale Steun Lijst-Discrepanties)  √ √ √ √ 
Satisfaction with relationship  √ √ √ √ 
Satisfaction with the 
appointment 
QUality Of care Through the patient’s Eyes 
(QUOTE) 
 √ √ √ 
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Screening and recruitment
Inclusion and 
randomization
Baseline measurements:
Intervention group:
 shared medical 
appointment
Control group:
Individual outpatient 
appointment
T1 questionnaires
T2 questionnaires
T1 questionnaires
T2 questionnaires
T=pre
T=0
T=3
T=2
T=1
CRAMP database
T3  questionnaires T3 questionnaires
Questionnaires:
‚" Use of care
‚" General health (SF 36, 
eQ5D, INQOL)
‚" Self efficacy, social support, 
relationship
Questionnaires:
‚" General health (SF 36, 
eQ5D, INQOL)
‚" Self efficacy, social support, 
relationship
‚" Satisfaction
Questionnaires:
‚" Use of care
‚" General health (SF 36, 
eQ5D, INQOL)
‚" Self efficacy, social support, 
relationship
‚" Satisfaction
1 week
3 months
3 months
Questionnaires:
‚" Use of care
‚" General health (SF 36, 
eQ5D, INQOL)
‚" Self efficacy, social support, 
relationship
‚" Satisfaction
Figure 1
